Since its discovery in the 1980s, the fatty acid hydroxylase flavocytochrome P450 (cytochrome P450) BM3 (CYP102A1) from Bacillus megaterium has been adopted as a paradigm for the understanding of structure and mechanism in the P450 superfamily of enzymes. P450 BM3 was the first P450 discovered as a fusion to its redox partner -a eukaryotic-like diflavin reductase. This fact fuelled the interest in soluble P450 BM3 as a model for the mammalian hepatic P450 enzymes, which operate a similar electron transport chain using separate, membrane-embedded P450 and reductase enzymes. Structures of each of the component domains of P450 BM3 have now been resolved and detailed protein engineering and molecular enzymology studies have established roles for several amino acids in, e.g. substrate binding, coenzyme selectivity and catalysis. The potential of P450 BM3 for biotechnological applications has also been recognized, with variants capable of industrially important transformations generated using rational mutagenesis and forced evolution techniques. This paper focuses on recent developments in our understanding of structure and mechanism of this important enzyme and highlights important problems still to be resolved.
Introduction
Since their discovery in the 1950s, the P450s (cytochromes P450) have been studied in enormous detail due to their involvement in a plethora of crucial cellular roles -from human drug and steroid metabolism through to the bacterial catabolism of unusual compounds as energy sources [1, 2] . The P450s are haem b-containing mono-oxygenase enzymes, often catalysing hydroxylation of hydrophobic substrate molecules. Molecular oxygen is bound to the haem iron and reductively activated to produce an oxyferryl radical cation intermediate. This 'active oxygen' compound I species attacks a substrate bound adjacent to the haem. Recent studies suggest that a preceding intermediate in the catalytic cycle (the ferric peroxy form or compound 0) may also be catalytically competent, at least with respect to epoxidation across carboncarbon double bonds [3] . However, computational studies indicate that compound I is a superior oxidant even for alkene epoxidation [4] . The key to the P450s' ability to cleave molecular oxygen is the axial ligation of haem iron by a conserved cysteine residue in the protein. The thiolate ligation is shared among the P450, NOS (nitric oxide synthase) and chloroperoxidase enzyme families -members of which all activate oxygen [5] . The structure and cellular roles of P450 enzymes are discussed in detail elsewhere [1, 2, 6] , and recent developments in characterization of P450 redox partner proteins are discussed in the accompanying paper by McLean et al. [7] .
The prokaryotic P450s are soluble enzymes and interact with soluble redox partners [7] . In contrast, eukaryotic P450s are, almost without exception, integral membrane proteins. The prokaryotic forms have proven easier to express and purify, and reconstitution of their activities with their soluble redox partners is also a simpler proposition than for the eukaryotic forms. The major redox partner for the eukaryotic P450s is the diflavin enzyme NADPH-CPR (where CPR stands for cytochrome P450 reductase), which is also an integral membrane protein [8] . Many early studies on structure, spectroscopy and enzymology of cytochrome P450 focused on the Pseudomonas putida cytochrome P450 cam enzyme (CYP101). P450 cam is an essential component of a plasmid-borne catabolic pathway for breakdown of Dcamphor as an energy source for the bacterium [9] . A huge volume of the fundamental work establishing the nature of cytochrome P450 was done with P450 cam, including the solution of the first P450 atomic structure and pivotal studies on the thermodynamic regulation of P450 catalysis [10, 11] . A problem perceived with respect to extrapolation of data from the class I P450 cam system to the medically relevant class II drug-metabolizing P450 forms was that the redox partners used were distinctly different. P450 cam is the terminal oxidase in a three-component redox chain, with electrons delivered from NADH to the FAD-containing putidaredoxin reductase, and on to the P450 by the 2Fe-2S ferredoxin putidaredoxin [9] . The eukaryotic class II P450s interact with the FAD-and FMN-containing CPR, which sources its electrons from NADPH [12] . Questions regarding e.g. structural differences in class I and II P450s to accommodate binding of the distinct redox partners and potential differences in electron transfer mechanism gave rise to nagging doubts as to the universal applicability of P450 cam. What might be more desirable as a tractable model for the class II P450s would be a soluble bacterial P450 with a CPR redox partner. The prokaryotic P450 that ultimately attained the status of a 'model system' for the class II eukaryotic P450s fulfilled this requirement, and had the additional advantage that the CPR was fused to the P450 in a single polypeptide chain. This paper will focus on the BM3 (Bacillus megaterium flavocytochrome P450 BM3) fusion system, highlighting recent advances in the structural and mechanistic characterizations of this intriguing enzyme.
Flavocytochrome P450 BM3: isolation, structural and catalytic properties
Miura and Fulco from the University of California at Los Angeles first isolated P450 BM3 as a fatty acid oxygenating enzyme activity from the cytosol of the soil bacterium B. megaterium [13] . The enzyme was shown to catalyse hydroxylation of saturated fatty acids of various chain lengths, close to the ω-terminal (typically ω − 1, ω − 2 and ω − 3 positions). The enzyme was isolated and named P450 BM3 -in recognition of the fact that two previous P450 enzymes have been identified in the bacterium. Subsequent studies demonstrated the multidomain nature of the enzyme and ultimately proved that the enzyme was a bona fide fusion of soluble P450 (N-terminal) to CPR, as predicted on the basis of the gene sequence [14, 15] . P450 BM3 is reduced by NADPH, with electrons transferred to the FAD cofactor in its CPR domain. Electrons are transferred singly from FAD to FMN within the CPR domain and then on to the haem iron in the SB (substrate-bound) P450 domain. Enzyme turnover studies demonstrated that flavocytochrome P450 BM3 had very high oxygenase activity with a range of fatty acids (> 15 000 min −1 with arachidonic acid). Transient kinetic studies revealed that rapid rates of electron transfer both within the reductase domain and between the reductase and the P450 underlie the catalytic efficiency of the enzyme [16] . Molecular dissection of the enzyme produced haemcontaining (P450) and diflavin (reductase) domains that retained UV-visible absorption and other spectroscopic properties characteristic of the flavocytochrome [17, 18] . However, molecular interactions between isolated domains and the reductase-to-P450 electron transfer rate were disrupted such that catalytic rates of fatty acid hydroxylation were diminished several fold [17] .
Thereafter, the race was on to determine structures for the enzyme and its domains. Atomic structures of the haem domain of the enzyme were solved in SF (substrate-free) and palmitoleic acid-bound forms [19, 20] . These structures indicated that a major structural rearrangement occurs between the two forms. However, whether this rearrangement is a direct consequence of substrate docking to the P450 is now uncertain given recent structural data on an A264E (Ala 264 → Glu) mutant form of the haem domain ( [21] and see below). In the SB form, the substrate is tethered at the mouth of the active site, held by electrostatic and hydrogenbonding interactions between its carboxylate group and the side chains of residues Arg 47 and Tyr 51 . The remainder of the alkyl chain extends into the active site and interacts with several hydrophobic residues [20] . The ω-terminus of the fatty acid is located distant from the haem iron, and movement of substrate closer to the haem iron was inferred from NMR studies on a sodium dithionite-reduced form of the fatty acid-bound haem domain [22] . Such movement is essential to relocate the substrate in order to position the relevant ω − 1 to ω − 3 target atoms in the immediate vicinity of compound I. However, it is not immediately obvious why the simple reduction of ferric iron to ferrous at the haem core should be sufficient to induce substrate relocation. Perhaps a more likely scenario is that the haem domain of the flavocytochrome undergoes conformational rearrangements, and that the equilibrium between conformational forms is affected by substrate binding and, potentially, by interaction with the redox partner. Substrate may re-position in different conformers or else be mobile within the active site. This hypothesis would also be consistent with recent structural studies on P450 BM3 mutants that exhibit novel haem iron ligand sets [21, 23] .
To date, crystallization and resolution of the atomic structure of the full-length flavocytochrome P450 BM3 has proven impossible, probably because of the multidomain nature of the enzyme and the presence of flexible linker regions between domains. A construct encoding the linked haem and FMN domains was created, and the purified FMN-haem domain protein crystallized. The structure was determined, but revealed proteolytic scission between the haem and FMN domains, and a non-stoichiometric complex of one FMN domain to two haem domains [24] . An extended sigma bond pathway for electron transfer between FMN and haem iron was hypothesized based on the structure, but distances involved are large and a more direct intercofactor electron transfer pathway is likely [24, 25] . Notwithstanding the problems of proteolysis and non-stoichiometry of domains, the FMN domain is seen to dock in a depression in the haem domain on the proximal face of the haem iron [6, 24] . In addition, the structure of the FMN domain was critical for explaining why the neutral, blue semiquinone form of the flavin is not stabilized by the BM3 FMN cofactor. The BM3 FMN is closely related to prokaryotic flavodoxins, which strongly stabilize the semiquinone form [25] . The semiquinone in the P450 BM3 FMN cofactor is destabilized in favour of the quinol form, probably as a result of altered charge distribution around the flavin and rigidity of the FMN-binding loop region by comparison with flavodoxins [24] . FMNs' tendency to become 'over-reduced' to the quinol form has interesting connotations with respect to catalytic activity of the enzyme, as discussed below.
The reductive inactivation enigma
Studies by Narhi and Fulco [15] revealed that fatty acid hydroxylase activity of P450 BM3 was inhibited progressively following preincubation of the enzyme with NADPH. No such inhibition occurs if fatty acid and NADPH are mixed simultaneously with the enzyme. Moreover, no significant inhibition of cytochrome c reduction rate (a process that requires electron transfer from the FMN cofactor) was observed on prereduction of P450 BM3 by NADPH, and fatty acid hydroxylation activity could be restored by oxidation of the prereduced enzyme [25] . The hypothesis developed was that the inactivation of fatty acid hydroxylation resulted from the development of FMN quinol as a 3-electron (or 4-electron) reduced form of the reductase domain accumulated. EPR analysis of P450 BM3 samples taken during active fatty acid oxygenation indicated that two semiquinone species (one a blue, neutral form and the other a red, anionic semiquinone) were present [26] . Potentiometric studies had revealed that the FAD flavin stabilized a blue semiquinone, thus the red semiquinone was proposed to form on the FMN [27] . Recently, stopped-flow studies were performed to analyse the dithionite-dependent reduction of the isolated BM3 FMN domain. Dithionite is a one-electron donor, and clear spectral evidence was obtained for transient formation of the red semiquinone on the FMN, before electronic disproportionation to form the thermodynamically favoured quinol [28] . It appears likely, then, that the formation of FMN quinol is at least partly responsible for the NADPH-dependent inactivation of P450 BM3 fatty acid hydroxylation. However, the phenomenon is by no means well understood. Further detailed kinetic and thermodynamic studies are required to ascertain whether, e.g. the FMN quinol is simply an inefficient electron donor to the P450 haem iron, or whether conformational alterations occur as a consequence of 'over-reduction', perhaps as a means of regulating enzyme activity if availability of fatty acid substrates is limited.
Completing the 'structural jigsaw' of flavocytochrome P450 BM3
With the structure of the haem domain of P450 BM3 solved in various forms [19, 20, 23, 29] and the FMN domain also determined in complex with the haem domain [24] , the last remaining segment of the flavocytochrome to be structurally characterized was the FAD/NADPH binding domain. The FAD domain is related to ferredoxin reductases and to the FAD domain of rat CPR, which has been structurally characterized [8] . In recent work, our group has crystallized the isolated FAD domain of P450 BM3 and resolved the atomic structure in the presence and absence of NADP (Figure 1 ). The likelihood is that electron transfer occurs directly between FAD and FMN cofactors in P450 BM3 (as would be expected for this highly efficient electron transferase system). Structural reorganization is almost certainly required to facilitate interaction of the FMN domain with the haem domain. Flexible linker regions between haem and FMN domains, and between FAD and FMN domains, probably facilitate interdomain communication [30] .
Deconvoluting enzyme mechanism using protein engineering
Rational mutagenesis has been used extensively to probe roles of various amino acids in substrate/ligand binding and catalysis. In the first mutagenesis study on BM3 (before structural characterization of the haem domain), the role of Trp 96 was investigated. This conserved residue was suggested to have a key role in electron transfer across the P450s [31] . Analysis of various P450 BM3 Trp 96 point mutants revealed that the residue was instead important for haem binding and for control of haem iron spin-state [32] . The subsequent atomic structure of the haem domain demonstrated a hydrogen bonding interaction between Trp 96 and haem propionate [19] . Phe 393 , another phylogenetically conserved P450 residue, was shown to be a regulator of the thermodynamic properties of the haem iron. The more positive reduction potential measured for the haem iron in F393A and F393H mutants was consistent with the faster flavin-to-haem electron transfer rates measured by stopped-flow methods. However, reductive activation of oxygen was severely compromised in the mutants, explaining diminished fatty acid hydroxylation rates and enabling rationalization of similar effects observed on catalytic turnover in comparable mutants of other P450 enzymes [33] . Another important amino acid in P450 BM3 is Phe 87 , the side chain of which lies above the haem plane and in proximity to the site for oxygen binding to the haem iron. The atomic structure of palmitoleate-bound BM3 haem domain indicated that the interaction of the terminal methyl group of substrate with the phenyl side chain of Phe 87 protected the former from oxidative attack by compound I, resulting in hydroxylation away from the ω-methyl group [20] . NMR studies of lauric acid turnover in a F87A mutant suggested that the effect of the mutation was to convert the enzyme into a near-exclusive fatty acid ω-hydroxylase (i.e. with negligible hydroxylation further down the lipid chain) [34] . However, later studies suggested that the position of oxidative attack was not at the ω-terminal and may in fact be removed further down the alkyl chain by replacement of Phe 87 with non-aromatic residues [35] . The latter results are perhaps more consistent with the notion that Phe 87 is a tether for the ω-methyl of fatty acid substrates. In this model, greater lateral motion of the fatty acid chain can occur when the tether is removed, enabling oxidative attack at positions further from the ω-terminal of the molecule. As discussed in the next section, an A264E [8] . The P450 BM3 FAD and FMN domains can be positioned in similar conformations to those of the respective rat CPR domains without significant steric clashes, consistent with the established rapidity of the redox reactions in this enzyme [37] . mutant in the P450 BM3 haem domain has also had farreaching consequences for our mechanistic understanding of the enzyme.
In the reductase domain of P450 BM3, several mutagenic studies have revealed, e.g. key residues involved in cofactor and coenzyme binding [36, 37] . A 'catalytic triad' of residues (Ser 830 , Cys 999 and Asp 1044 ) in P450 BM3 is extensively conserved in the diflavin reductase family to which the CPR enzymes belong. Recent research on C999A variants of BM3 reductase and FAD domains showed that the rate of hydride transfer from NADPH to FAD was substantially decreased, but that thermodynamic properties of the flavin were not significantly altered. Also, a stable charge-transfer species formed on reaction between NADPH and the wild-type FAD domain was not observed for the C999A FAD domain. These results were consistent with previous studies of mammalian CPR, and indicated a role for Cys 999 both in enhancement of hydride transfer rate to FAD cofactor and in stabilizing the FADH 2 -NADP + complex of P450 BM3 [37] . Interestingly, the triad cysteine is absent from the wild-type form of human NR1 (novel reductase 1), a cancer-related diflavin reductase [38] . NR1 is the slowest of all the diflavin reductases, with a limiting rate of NADPH-to-FAD hydride transfer (k lim ) of only approx. In further recent engineering studies of BM3 reductase and FAD domains, an aromatic amino acid that stacks over the FAD cofactor (Trp 1046 ) was replaced with both histidine and alanine residues. The mutants showed a huge switch in coenzyme specificity from NADPH towards NADH (∼6000-fold with the W1046A FAD domain) [39] . NADH is a substantially cheaper coenzyme than NADPH, and these mutants have potential for exploitation in biotechnological processes (see below).
Conformational equilibria and catalytic control in the BM3 haem domain
Structures of SF and SB forms of the BM3 haem domain revealed a major structural rearrangement in the P450 [19, 20] . A substrate-induced conformational switch was inferred. However, recent structural analysis of the A264E mutant haem domain has offered a different explanation. Ala 264 is located in the I helix of P450 BM3, a segment of the P450 rich in residues with roles in catalysis and substrate binding. Amino acid alignments showed that the corresponding residue in several related eukaryotic CYP4 family P450s was a glutamate. This glutamate residue was shown to form (in a turnover-dependent manner) a covalent bridge to the haem 5-methyl group in these P450s. The A264E mutant of P450 BM3 did not form a covalent bridge, but spectroscopic studies indicated instead that the glutamate side chain replaced water as an axial ligand to the haem iron in a proportion of the SF form of the A264E haem domain. Addition of fatty acids to the mutant forced this glutamate ligand on/off equilibrium towards a completely glutamate-ligated form [21] . Atomic structures were solved for SF and SB A264E haem domains, confirming the results of spectroscopic analysis. In the SF form, there were two molecules in the asymmetric unit. One had the 'normal' Cys-Fe-H 2 O ligand set and the other had Cys-Fe-Glu. In the 'ligand off' form, the Glu 264 side chain interacted with the side chain of Phe 87 . In the palmitoleatebound form, a single Cys-Fe-Glu set was observed (Figure 2 ) [23] . In both SF and SB forms of the A264E haem domain (regardless of whether the haem was co-ordinated by Glu 264 ), the conformation adopted was that seen in the SB wild-type enzyme. Fatty acid substrates were found to bind tighter to the A264E haem domain compared with wild-type BM3, suggesting that the mutation itself had altered the conformational equilibrium between SF and SB forms in solution (regardless of the presence of substrate) and that fatty acids bind more tightly to (and stabilize) the SB conformation. Thus we conclude that both SF and SB conformations are present in solutions of the fatty acid-free BM3 haem domain, and that the equilibrium between these forms can be altered by protein mutations. The SB conformation is that which binds more tightly to substrates, rather than one that forms following substrate association [23] . The fact that the A264E enzyme retains considerable fatty acid hydroxylase activity points strongly to further structural reorientations (that displace Glu 264 and enable oxygen binding to haem iron) that occur subsequent to interaction with the CPR domain and/or haem iron reduction.
Biotechnological exploitation of flavocytochrome P450 BM3
Several P450s (particularly the bacterial forms) are regioand stereoselective mono-oxygenases. As such, they have the potential to catalyse the production of high-value oxygenated 
P450 BM3
The structure reveals two molecules (A, B) in the asymmetric unit cell.
(A) Axial co-ordination of the haem iron by both Cys 400 (proximal) and the Glu 264 side chain (distal) and (B) the interaction of glutamate instead with the phenyl side chain of residue Phe 87 . In (B) water is the distal ligand to the haem iron. Both molecules adopt the protein conformation previously observed for SB wild-type P450 BM3 haem domain [23] .
organic molecules for use as, e.g. chiral synthons in synthetic pathways. Enzyme-mediated product formation is a relatively 'clean' technique that has obvious advantages over 'traditional' organic chemistry methods. Large excesses of desired chiral products can be formed enzymatically. P450 BM3 is an obvious target for such applications, since it is a very high activity, single-component enzyme. Numerous protein engineering studies have demonstrated the pliability of its active site and excellent structural data provide the basis for further engineering to promote recognition of desired substrates [30] . Recent work producing NADH-specific variants make P450 BM3 even more attractive and cost-effective for biotechnological processes [39] . While the field is still in its relative infancy, significant steps have been made to create biotechnologically more applicable variants. For instance, rational mutagenesis of the central portion of the BM3 substrate-binding site produced mutants with considerably enhanced activities such as short chain (C 4 -C 8 ) alkanoic acid hydroxylases [40] . A forced evolution approach generated a high activity alkane hydroxylase with several mutations scattered throughout the protein scaffold [41] . In recent work, our group has characterized reactivity of wild-type and Phe 87 mutant forms of P450 BM3 with several alkenes. Rates of more than 1000 turnovers · min −1 were obtained with a number of substrates, and different product profiles were obtained with wild-type and mutant forms (S.A. Murray, R.A. Holt, N.S. Scrutton and A.W. Munro, unpublished work). P450 BM3 clearly has several applications in the biotechnology arena, and its potential will be increasingly tapped in the coming years.
'We are not alone' -BM3 homologues and other P450:reductase fusion enzymes
For several years, P450 BM3 stood alone as the only characterized P450:reductase fusion enzyme -casting some doubt on the broader importance of this type of fusion enzyme in biology. However, the discovery that NOS, a key cell-signalling enzyme in eukaryotes, was also a flavocytochrome of similar construction to P450 BM3 (cysteinate-co-ordinated haem-containing oxygenase domain fused to a CPR module), provided the first clue that this type of P450:CPR fusion would be widespread in nature [42] . Subsequently, the BM3-type enzyme has been recognized in various prokaryotes and lower eukaryotes, with genome sequences continuing to reveal new members for the CYP102 family of BM3 (e.g. from Bacillus anthracis, Bradyrhizobium japonicum, Streptomyces avermitilis and Gibberella moniliformis). The only other direct homologues characterized at the protein level are CYP102A2 and CYP102A3 from Bacillus subtilis. Both are also NADPH-dependent fatty acid hydroxylases, but display distinct differences in substrate specificity compared with P450 BM3 -with strong selectivity for long-chain unsaturated and branched-chain fatty acids [43] . Branchedchain fatty acids are prevalent in the B. subtilis membrane. A P450 BM3 homologue is present in the heavy metal-tolerant bacterium Ralstonia metallidurans, which also encodes a novel type of P450:reductase fusion enzyme. The reductase in this new P450 class resembles the FMN-and 2Fe-2S-containing phthalate dioxygenase reductase, and the P450 has significant similarity with a Rhodococcus sp. P450 known to degrade thiocarbamate herbicides [44] . Doubtless, genome sequencing studies will continue to reveal new types of P450:reductase fusion enzymes that have evolved to provide efficient P450 oxygenase activities tailored to the specific physiological requirements of the host organism.
Summary and future prospects
P450 BM3 has been, and continues to be, an important model system for the comprehension of structure-functionmechanism relationships in the P450 superfamily. In addition, BM3 has clear biotechnological potential [30, 40, 41] . Despite advances in structural biology of mammalian cytochromes P450 and their reductase systems, BM3 remains a tractable and valuable model system due to its convenient modular construction, soluble nature and the detailed understanding of its structural and catalytic properties. Several issues pertaining to, e.g. conformational dynamics and thermodynamic control over electron transfer remain to be resolved. These and other topics of broad general relevance in the P450 field maintain BM3 as a pivotal member of its superfamily.
